An Emerging Autoimmune Neuroinflammatory Disease: Myelin Oligodendrocyte Glycoprotein Antibody Disease.

Ann Afr MedSep 15, 2025 (epub)
Case ReportNeurologyOpen access

Satbir Kaur Malik, Atharvan Sharma Mangalapalli, Hemanjali Avuthu

✦ AI-curated · Sources linked

Case in brief

A 40-year-old woman presented with fever, acute left visual impairment and pain with eye movement, ataxia, dizziness, bitemporal headache, and urinary retention. Cerebrospinal fluid showed lymphocytic pleocytosis, serum anti-MOG antibodies were positive at 1:100, and MRI demonstrated lesions in the diencephalon, brainstem, periventricular white matter, and conus medullaris. After intravenous methylprednisolone followed by a tapering course of oral prednisolone, she recovered completely. At one-year follow-up, serum anti-MOG antibodies were negative and brain and spinal MRI lesions had resolved.

What made this case unusual

The presentation combined optic symptoms and multifocal brain lesions with conus medullaris involvement and urinary retention, alongside positive serum anti-MOG antibodies.

Diagnostic / clinical pearl

In a patient with multifocal demyelinating lesions and a compatible clinical syndrome, serum anti-MOG antibody testing can help identify MOGAD as distinct from multiple sclerosis and AQP4-IgG-positive NMOSD.

Source

Published in Ann Afr Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.